PARION SCIENCES, INC.
Biotech · Private
Small molecule ENaC blocker (P-1155) combined with osmolyte for mucus rehydration in muco-obstructive lung diseases
- Grants
- $2.5M
- 3 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 28 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Novel Dual Acting Antibiotics for Pulmonary Disease | $274,173 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel ENaC Blocker/Osmolyte Inhalation Solution for the Treatment of Muco-Obstructive Lung Diseases | $295,700 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel ENaC Blocker/Osmolyte Inhalation Solution for the Treatment of Muco-Obstructive Lung Diseases | $1,971,749 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2917 | STELLATE DNA LLC | — | — |
| 2918 | Propeller Bio | — | — |
| 2919 | EICOSIS LLC | — | — |
| 2920 | PARION SCIENCES, INC. | — | — |
| 2921 | VINCERE BIOSCIENCES INC | — | — |
| 2922 | AADI, LLC | — | — |
| 2923 | NAUTILUS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Biphenyl-substituted Epithelial Sodium Channel Blocking Compoundsapplication
- Bicyclic-substituted Epithelial Sodium Channel Blocking Compoundsapplication
- 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDEgranted
- Novel Monothiol Mucolytic Agentsgranted
- 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL) CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDEgranted
- Aerosol Delivery Systems, Compositions And Methodsapplication
- Dendrimer Like Amino Amides Possessing Sodium Channel Blocker Activity For The Treatment Of Dry Eye And Other Mucosal Diseasesgranted
- Novel Prodrugs Of Dithiol Mucolytic Agentsgranted
- 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- Carboxamide Compoundsapplication
- Sodium Channel Blockersapplication
- Methods Of Treatmentgranted
- 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- Carboxamide Compoundsgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.